ALCON AG

NYSE: ALC (Alcon Inc.)

Kemas kini terakhir: 3 hari lalu, 4:54PM

78.20

-1.11 (-1.40%)

Penutupan Terdahulu 79.31
Buka 79.29
Jumlah Dagangan 1,908,816
Purata Dagangan (3B) 2,173,034
Modal Pasaran 38,559,272,960
Harga / Pendapatan (P/E TTM) 37.24
Harga / Pendapatan (P/E Ke hadapan) 23.20
Harga / Jualan (P/S) 3.87
Harga / Buku (P/B) 1.68
Julat 52 Minggu
71.55 (-8%) — 99.20 (26%)
Tarikh Pendapatan 11 Nov 2025
Hasil Dividen (DY TTM) 0.35%
Margin Keuntungan 11.28%
Margin Operasi (TTM) 13.30%
EPS Cair (TTM) 2.25
Pertumbuhan Hasil Suku Tahunan (YOY) 0.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 41.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.63%
Nisbah Semasa (MRQ) 2.70
Aliran Tunai Operasi (OCF TTM) 2.12 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 1.18 B
Pulangan Atas Aset (ROA TTM) 2.74%
Pulangan Atas Ekuiti (ROE TTM) 5.23%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Bercampur Bercampur
Medical Instruments & Supplies (Global) Bercampur Menurun
Stok Alcon Inc. Menaik Menurun

AISkor Stockmoo

2.4
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 2.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALC 39 B 0.35% 37.24 1.68
RMD 37 B 0.21% 25.64 6.10
STVN 6 B 0.21% 39.63 3.82
BDX 55 B 0.54% 33.01 2.18
WST 16 B 0.19% 34.84 6.54
BLCO 6 B - - 0.850

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.13%
% Dimiliki oleh Institusi 68.26%

Pemilikan

Nama Tarikh Syer Dipegang
Zurcher Kantonalbank (Zurich Cantonalbank) 30 Sep 2025 8,493,154
Ako Capital Llp 30 Sep 2025 7,974,364
Harding Loevner Lp 30 Sep 2025 5,482,424
Julat 52 Minggu
71.55 (-8%) — 99.20 (26%)
Julat Harga Sasaran
85.00 (8%) — 100.00 (27%)
Tinggi 100.00 (Mizuho, 27.88%) Beli
Median 91.00 (16.37%)
Rendah 85.00 (Stifel, 8.70%) Beli
Purata 92.71 (18.56%)
Jumlah 6 Beli, 1 Pegang
Harga Purata @ Panggilan 76.30
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BTIG 24 Nov 2025 91.00 (16.37%) Beli 76.25
13 Oct 2025 91.00 (16.37%) Beli 72.60
Baird 13 Nov 2025 98.00 (25.32%) Beli 78.61
Needham 12 Nov 2025 98.00 (25.32%) Beli 79.44
Mizuho 11 Nov 2025 100.00 (27.88%) Beli 77.36
Keybanc 21 Oct 2025 91.00 (16.37%) Beli 75.76
Barclays 13 Oct 2025 86.00 (9.97%) Pegang 72.60
Stifel 29 Sep 2025 85.00 (8.70%) Beli 74.11

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
11 Nov 2025 Pengumuman Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
10 Nov 2025 Pengumuman Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 Pengumuman STAAR Surgical Announces Amendments to Alcon Merger Agreement
04 Nov 2025 Pengumuman Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
04 Nov 2025 Pengumuman Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
31 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
27 Oct 2025 Pengumuman STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
24 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
24 Oct 2025 Pengumuman Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
23 Oct 2025 Pengumuman Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
20 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
20 Oct 2025 Pengumuman Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
17 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
15 Oct 2025 Pengumuman Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
14 Oct 2025 Pengumuman Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
10 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
08 Oct 2025 Pengumuman Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
08 Oct 2025 Pengumuman STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
08 Oct 2025 Pengumuman Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
07 Oct 2025 Pengumuman Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
06 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
06 Oct 2025 Pengumuman Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
03 Oct 2025 Pengumuman Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
30 Sep 2025 Pengumuman Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
24 Sep 2025 Pengumuman Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
22 Sep 2025 Pengumuman STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
22 Sep 2025 Pengumuman Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
16 Sep 2025 Pengumuman STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
16 Sep 2025 Pengumuman Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
08 Sep 2025 Pengumuman Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
Papar semua
Hasil Dividen (DY TTM) 0.35%
Purata Hasil Dividen 4T 0.26%
Nisbah Pembayaran 11.81%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 May 2024 08 Apr 2024 16 May 2024 0.2644 Tunai
10 May 2023 30 Mar 2023 12 May 2023 0.2356 Tunai
29 Apr 2022 24 Mar 2022 05 May 2022 0.2083 Tunai
04 May 2021 24 Mar 2021 06 May 2021 0.0909 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 0.264 1 0.31
2023 0.236 1 0.30
2022 0.208 1 0.30
2021 0.091 1 0.10

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda